Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M403453200 on April 19, 2004

J. Biol. Chem., Vol. 279, Issue 26, 27584-27590, June 25, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
279/26/27584    most recent
M403453200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, J. M. R.
Right arrow Articles by Guy, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, J. M. R.
Right arrow Articles by Guy, R. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Quantitative Proteomics of the Thyroid Hormone Receptor-Coregulator Interactions*

Jamie M. R. Moore{ddagger}, Sarah J. Galicia{ddagger}§, Andrea C. McReynolds{ddagger}, Ngoc-Ha Nguyen{ddagger}, Thomas S. Scanlan{ddagger}, and R. Kiplin Guy{ddagger}||

From the Departments of {ddagger}Pharmaceutical Chemistry and Molecular & Cellular Pharmacology, University of California at San Francisco, San Francisco, California 94143-2280

Received for publication, March 29, 2004 , and in revised form, April 19, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The thyroid hormone receptor regulates a diverse set of genes that control processes from embryonic development to adult homeostasis. Upon binding of thyroid hormone, the thyroid receptor releases corepressor proteins and undergoes a conformational change that allows for the interaction of coactivating proteins necessary for gene transcription. This interaction is mediated by a conserved motif, termed the NR box, found in many coregulators. Recent work has demonstrated that differentially assembled coregulator complexes can elicit specific biological responses. However, the mechanism for the selective assembly of these coregulator complexes has yet to be elucidated. To further understand the principles underlying thyroid receptor-coregulator selectivity, we designed a high-throughput in vitro binding assay to measure the equilibrium affinity of thyroid receptor to a library of potential coregulators in the presence of different ligands including the endogenous thyroid hormone T3, synthetic thyroid receptor {beta}-selective agonist GC-1, and antagonist NH-3. Using this homogenous method several coregulator NR boxes capable of associating with thyroid receptor at physiologically relevant concentrations were identified including ones found in traditional coactivating proteins such as SRC1, SRC2, TRAP220, TRBP, p300, and ARA70; and those in coregulators known to repress gene activation including RIP140 and DAX-1. In addition, it was discovered that the thyroid receptor-coregulator binding patterns vary with ligand and that this differential binding can be used to predict biological responses. Finally, it is demonstrated that this is a general method that can be applied to other nuclear receptors and can be used to establish rules for nuclear receptor-coregulator selectivity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Thyroid hormone (3,5,3'-triido-L-thyronine, T3)1 regulates multiple physiologic processes in development, growth, and metabolism (1, 2). Most T3 actions are mediated through the thyroid hormone receptors (TR), which regulate transcription of target genes either positively or negatively in response to hormone binding. There are two different genes that express different TR subtypes, TR{alpha} and TR{beta}. Each transcript can be alternatively spliced generating different isoforms (TR{alpha}1, TR{alpha}2, TR{beta}1, TR{beta}2,) (3, 4). While most of these isoforms are widely expressed, there are distinct patterns of expression that vary with tissue and developmental stage. In particular, TR{beta}2 is found almost exclusively in the hypothalamus, anterior pituitary, and developing ear. In addition, mice deficient in either TR{alpha} or TR{beta} display unique phenotypes, suggesting that the different TR isoforms have unique regulatory roles (5-10).

The thyroid hormone receptors belong to a superfamily of proteins known as the nuclear hormone receptors (NR). Like other members of the NR superfamily, TR has three functional domains: an N-terminal transactivation domain (NT), a central DNA binding domain (DBD), and a C-terminal ligand binding domain (LBD) (11). The DBD of TR recognizes short, repeated sequences of DNA found in T3-responsive genes, termed the thyroid hormone response elements (TREs). TR can bind to a TRE as a monomer, homodimer, or heterodimer with the retinoid X receptor (RXR) (12). However, receptor activation from the heterodimer complex is the best characterized to date. Both liganded and unliganded TR bind to TREs. In the absence of T3, TR associates with corepressor proteins at the TRE maintaining the chromatin in a compact state and therefore repressing gene activation. Upon binding of T3, TR undergoes a conformational change releasing corepressor proteins and allowing for the interaction with coactivator proteins that enhance TRE-driven gene transcription.

Structural, biochemical, and genetic studies have provided a considerable amount of information about NR-coregulator interactions. The best studied coregulators belong to the p160 protein family of steroid receptor coactivators (SRC) (13). Members of this family include SRC1, SRC2 (GRIP1/TIF2), and SRC3 (AIB1/TRAM1/RAC3/ACTR). These proteins contain several functional domains including the nuclear receptor interaction domain (NID), and two activation domains that interact with other coregulatory proteins CBP/p300 (AD-1) and CARM-1 (AD-2) (Fig. 1A). Within the NID there are three repeated motifs with the consensus sequence LXXLL, often termed the NR box. In addition there is a unique fourth LXXLL motif found in the extreme C terminus of an alternatively spliced variant of SRC1, SRC1-a. Several investigations have shown that the LXXLL motif is necessary and sufficient for interaction with NR (14, 15). Further structural work with a coregulator NR box peptide and liganded TR has revealed that the LXXLL binds to a hydrophobic groove in the TR-LBD as an {alpha}-helix (16). Other coregulators include CREB-binding protein (CBP)/p300 (17, 18), thyroid receptor-activating protein (TRAP)/vitamin D receptor-interacting protein (DRIPs)/peroxisome proliferating-activated receptor-binding protein (PBP) (19, 20), androgen receptor activator 70/55 (ARA70/55) (21, 22), receptor-interacting protein 140 (RIP140) (23), PPAR{gamma} coactivator 1 (PGC-1) (24), thyroid receptor-binding protein (TRBP)/PPAR-interacting protein (PRIP) (25, 26), DAX-1 (27), and small heterodimer partner (SHP) (28). The interaction of these coregulators with nuclear receptors is also mediated by LXXLL motifs. An analogous motif, I/LXXII, has been identified in corepressors such as nuclear receptor corepressor (NCoR) and silencing mediator of retinoic acid (SMRT), and structural studies have shown that the binding sites for coactivators and corepressors partially overlap (29).



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 1.
Coregulator peptides. A, block diagram of SRC1 identifying some of the functional domains. The nuclear interaction domain (NID) contains three nuclear receptor interaction domains (NR boxes) that are known to interact with NR (SRC1-1, SRC1-2, SRC1-3). The activation domains AD-1 and AD-2 interact with other known coregulators including p300/CBP and CARM-1. SRC1 has two isoforms, SRC1a and SRC1e. SRC1-a has an additional NR box at the C terminus designated SRC1-4 that has been shown to interact with some NR. B, sequence alignment of the coregulator peptides tested in this study. The conserved NR box, LXXLL, is enclosed in a box. Negative control peptides were also synthesized with leucine +4 and +5 replaced with alanines (LXXAA). * denotes omitted peptide sequences that were not recovered after synthesis.

 
There is a large pool of coregulators available for interaction with TR. Although there appears to be some functional redundancy within the SRCs, there is also evidence that SRCs have distinct biological regulatory roles. While mice deficient in SRC1 exhibit resistance to thyroid hormone (RTH), the phenotypes for mice deficient in SRC2 and SRC3 are distinct with no evidence of RTH (30-32). These studies, along with recent work with the progesterone and glucocorticoid receptors, have demonstrated that interaction with specific coregulators can elicit specific biological responses (33). However, it remains unclear how NRs discriminate between different coregulators. In this study we sought to define rules that govern TR-coregulator selectivity.

Combinatorial peptide libraries have been used to define NR-coregulator specificity, and have revealed that the sequences immediately flanking the NR box are critical for specificity (34, 35). However the peptides in these studies were generated from random libraries that do not represent the true NR box sequences. Other investigations focused on defining SRC NR box selectivity using a subset of coregulator NR boxes from the SRCs. This work has shown that ligands can allosterically modulate the coregulator binding pocket and therefore differentially alter specific SRC recruitment and NR box usage (36-38). However, to date there has been no comprehensive study of the interactions of TR and natural coregulator NR boxes. To address this issue, we designed an in vitro binding assay to measure the equilibrium binding of TR{beta} to a library of potential coregulators in a high-throughput manner using fluorescence polarization. With this method, binding constants for TR{beta} to coregulator NR boxes were determined in a consistent format, including NR boxes from SRCs and nine other known coregulators. In addition the TR{beta}-coregulator binding patterns for three different ligands including T3, the synthetic TR{beta}-selective agonist GC-1, and the T3 antagonist NH-3 were defined. This quantitative information can be used to establish rules for TR{beta} coregulator selectivity, and these rules can be used for predicting biological responses.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Ligand Synthesis—GC-1 and NH-3 were synthesized as previously described (39, 40).

Protein Expression and Purification—Human TR{beta} LBD (His6; residues Glu202-Asp461) was expressed from a pET28a construct (Novagen) in BL21(DE3) (20 °C, 0.5 mM isopropyl-1-thio-{beta}-D-galactopyranoside added at OD600 = 0.6) as previously described (15). Cells were harvested, resuspended in sonication buffer (20 mM Tris, 300 mM NaCl, 0.025% tween, protease inhibitors, 10 mg of lysozyme, pH 7.5, 30 min on ice), and sonicated for 3 x 3 min on ice. The lysed cells were centrifuged at 100,000 x g for 1 h, and the supernatant was loaded onto Talon resin (Clontech). Liganded protein was eluted with 500 mM imidazole plus ligand (3,3',5-triiodo-L-thyronine (Sigma); GC-1; or NH-3). Protein purity was assessed by SDS-PAGE and HPSEC, and protein concentration measured by the Coomassie protein assay.

Peptide Library Synthesis—Coregulator peptides consisting of 20 amino acids with the general motif of CXXXXXXXLXXL/AL/AXXXXXXX were constructed, where C is cysteine, L is leucine, A is alanine, and X is any amino acid. The sequences of all the coregulator peptides were obtained from human isoform candidate genes (SRC1/AAC50305, SRC2/Q15596, SRC3/Q9Y6Q9, PGC-1/AAF19083, TRAP220/Q15648, TRBP/Q14686, TRAP100/Q75448, ARA70/Q13772, ARA55/NP_057011, p300/Q92831, RIP140/P48552, DAX-1/P51843, SHP/Q15466). The peptides were synthesized in parallel using standard fluorenylmethoxycarbonyl (Fmoc) chemistry in 48 well synthesis blocks (FlexChem System, Robbins) (41). Preloaded Wang (Novagen) resin was deprotected with 20% piperidine in dimethylformamide. The next amino acid was then coupled using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (2.38 eq), Fmoc-protected amino acid (2.5 eq), and diisopropylethylamine (5 eq) in anhydrous dimethylformamide. Coupling efficiency was monitored by the Kaiser test. Synthesis then proceeded through a cycle of deprotection and coupling steps until the peptides were completely synthesized. The completed peptides were cleaved from the resin with concomitant side chain deprotection (81% trifluoroacetic acid, 5% phenol, 5% thioanisole, 2.5% ethanedithiol, 3% water, 2% dimethylsulfide, 1.5% ammonium iodide), and the crude product was evaporated using a Speedvac (Gene-Vac). Reversed-phase chromatography followed by mass spectrometry (MALDI-TOF/ESI) were used to purify the peptides. The purified peptides were lyophilized. A thiol reactive fluorophore, 5-iodoacetamidofluorescein (Molecular Probes), was then coupled to the N-terminal cysteine following the manufacturer's protocol. Labeled peptide was isolated using reversed-phase chromatography and mass spectrometry. Peptides were quantified using UV spectroscopy. Purity was assessed using LCMS (Supplemental Information).

Direct Binding Assay—Using a BiomekFX in the Center for Advanced Technology (CAT), hTR{beta}-LBD was serially diluted from 70-0.002 µM in binding buffer (50 mM sodium phosphate, 150 mM NaCl, pH 7.2, 1 mM dithiothreitol, 1 mM EDTA, 0.01% Nonidet P-40, 10% glycerol) containing 140 µM ligand (T3, GC-1, or NH-3) in 96-well plates. Then 10 µl of diluted protein was added to 10 µl of fluorescent coregulator peptide (20 nM) in 384-well plates yielding final protein concentrations of 35-0.001 µM and 10 nM fluorescent peptide concentration. The samples were allowed to equilibrate for 30 min. Binding was then measured using fluorescence polarization (excitation {lambda} 485 nm, emission {lambda} 530 nm) on an Analyst AD (Molecular Devices). Two independent experiments were assayed for each state in quadruplicate. Data were analyzed using SigmaPlot 8.0 (SPSS, Chicago, Il), and the Kd values were obtained by fitting data to the following equation (y = min + (max - min)/1 + (x/Kd) Hill slope).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Coregulator Peptide Library—A library of known coregulator peptides consisting of the LXXLL sequence plus 7-8 additional flanking residues at each terminus was synthesized (Fig. 1B). Previous screens with coactivator peptides established amino acid residues at +6 to +12 as critical for binding (38, 42). To capture these specificity determinants, peptides of 20-amino acid length were generated. Additionally, negative control peptides were made for each coregulator NR box by replacing L+4 and L+5 with alanine (LXXAA), as this substitution has been shown to abolish interactions with NR (38). A thiol reactive fluorescent probe was covalently attached to each peptide via a cysteine positioned at the N terminus of each peptide. The coregulator peptides are listed in the far left column of Fig. 1B, where SRC1-1, SRC1-2, SRC1-3 represent the first, second, and third NR boxes in SRC1, respectively. This nomenclature, first proposed by O'Malley, is applied to all of the coregulator peptides studied throughout this report (30). All peptide probes were synthesized in parallel using the Fmoc strategy and purified by RP-HPLC. Identity and purity were confirmed using HPLC and MALDI-TOF or LCMS (Supplemental Information). Seven targeted coregulator NR boxes, TRAP100-1, TRAP100-5, RIP140-2, RIP140-4, TRAP220-1(-), TRBP-1(-), and TRAP100-6(-), are omitted as they could not be synthesized or purified after several attempts.

Coregulator Peptides Bind to hTR{beta}-LBD in Four Different Binding Modes—Initial peptide binding studies were carried out with SRC2-2, and the ligand binding domain of the human thyroid hormone receptor {beta} (hTR{beta}-LBD) in the presence of T3. As shown in Fig. 2A, SRC2-2 binds to TR{beta} in a saturable dose-dependent manner with a measured Kd of 0.7 µM, consistent with literature reports (0.8 µM) (15). We also confirmed that this interaction was specific by carrying out binding studies with a mutated SRC2-2 peptide (LXXAA, SRC2-2(-)). The trace observed in Fig. 2A reveals that SRC2-2(-) does not interact with TR{beta} in the presence of T3.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 2.
TR{beta}-coregulator binding isotherms in the presence of T3. Panel A, the binding of TR{beta} SRC2-2 is plotted in dark green to signify that this is a saturable binding curve where a measurable Kd = 0.7 µM is extracted by fitting to the equation (y = min + (max - min)/1 + (x/Kd) Hill slope). The binding of TR{beta} to the negative control SRC2-2 peptide is also shown in red. Panel B, the binding curve for SRC1-3 is shown in light green. This binding curve appears to be reaching saturation, but no visible plateau is observed. The Kd is reported as 10.1-30 µM. Panel C, The binding curve for SRC3-3 is shown in gray. Polarization is increasing with TR{beta} concentration but does not appear to be reaching saturation. The Kd is reported as >30 µM. Panel D, the binding curve for TRAP220-2 is plotted in red indicating that no binding is observed. The solid circles denote the native NR box peptides, solid lines represent fitted curves for native NR box peptides, open red circles represent negative NR box peptides (LXXAA), and the dashed red line is the fitted curve for the negative NR box peptide.

 
To further elucidate the coregulator binding pattern of TR{beta} in the presence of T3, direct binding assays were carried out with the entire coregulator peptide library. This set of experiments was executed by maintaining a constant concentration of coregulator peptide (10 nM) and varying the TR{beta} concentration from 0.001-35 µM in the presence of saturating amounts of T3 (90 µM). The results revealed that the 34 different coregulator peptides bound to liganded TR with varying degrees of affinity. Individual Klotz plots were constructed for each coregulator peptide. This analysis revealed four different binding modes. Example equilibrium affinity curves are summarized in Fig. 2 (A-D) and Kd value ranges are reported in Fig. 3A. In no case did the negative peptide controls bind to liganded TR{beta}.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 3.
Coregulator binding patterns and specificity determinants. A, the structure of the TR{beta} ligands tested; endogenous thyroid hormone T3, synthetic TR{beta}-selective agonist GC-1, and T3 antagonist NH-3. The equilibrium binding constants for TR{beta}-coregulator NR boxes are reported for each ligand. The coregulator peptides are listed in the left column where SRC1-1, SRC1-2, SRC1-3, SRC1-4 represent the first, second, third, and fourth NR box in SRC1, respectively. Each color represents a unique Kd range as defined by the legend on the left. Significant differences between TR{beta}·T3 and TR{beta}·GC-1 are boxed in black. B, representative coregulator peptide is listed for TR{beta}·T3, TR{beta}·GC-1, ER{alpha}·E2 with amino acids highlighted in green representing amino acids that convey specificity for each NR·ligand state. The information for ER{alpha}·E2 was extracted from two sources for comparative purposes: 1) a time-resolved fluorescence assay conducted with SRCs (36) and 2) a phage peptide library screen with ER{alpha}·E2 (35). {Phi} denotes hydrophobic amino acids, and {zeta} represents hydrophilic amino acids.

 
The first binding mode consisted of peptides that bound in a dose dependent and saturable manner (Fig. 2A) where a clear plateau was reached within the protein concentration range studied. Eight coregulator peptides exhibited this mode: SRC2-1, SRC2-2, SRC2-3, TRAP220-1, TRBP-1, p300, RIP140-5, and DAX1-3. The Kd values for this class ranged from 0.7 to 10 µM.

The next binding mode included peptides where binding appeared to be reaching saturation but did not have a clear plateau, as defined by at least two points with indistinguishable y-ordinates (Fig. 2B). This assumption is based on previous binding studies conducted with these coregulator peptides where similar changes in polarization values were observed for saturating binding isotherms (data not shown). These peptides bound to TR{beta} with a Kd range of 10-30 µM and included SRC1-2, SRC1-3, SRC3-2, TRAP220-2, TRBP-2, and ARA70. To accurately obtain Kd values, however, the binding studies would need to be carried out at protein concentrations varying from 1-300 µM as this would give the widest range of polarization values. Working with TR{beta} protein concentrations higher than 100 µM is problematic due to protein aggregation and decreased protein stability. In order to reflect the inability to obtain an unambiguous Kd value, we report a Kd range,10-30 µM, for coregulator peptides that exhibit this binding mode.

The third binding mode is one in which polarization increases with protein concentration but does not seem to be reaching saturation. This mode is exemplified by SRC3-3 (Fig. 2C) where the polarization of SRC3-3 slowly increases with TR{beta} concentration. Other coregulators included in this category are SRC1-1, SRC3-1, SRC3-3, RIP140-3, RIP140-8, and SHP. The binding isotherms for this group suggest that the coregulator peptides are binding non-specifically or that they bind with a Kd value significantly above the working assay range, (e.g. >30 µM). This class of coregulator peptides is distinguished from the final group of peptides where no binding is observed (Fig. 2D).

T3 Recruitment of Coregulators—We report here the first comprehensive investigation of coregulator recruitment to liganded TR{beta} with 12 different coregulators and 32 unique NR boxes as well as appropriate negative controls (LXXAA). Of the 32 coregulator peptides tested, 20 appear to interact with TR{beta} in the presence of T3 with varying degrees of affinity. The strongest recruitment observed was with SRC2-2 which exhibited a Kd of 0.7 µM ± 0.2. This was followed by TRBP-1 (Kd = 1.8 µM ± 0.1), RIP140-5 (Kd = 2.5 µM ± 0.4), TRAP220-1 (Kd = 2.7 µM ±1.1), DAX1-3 (Kd = 3.6 µM ± 2.3), SRC2-3 (Kd = 4.5 µM ± 1.5), SRC2-1 (Kd = 6.0 µM ± 2.0), and p300 (Kd = 9.2 µM ± 2.8). The coregulator peptides that clearly did not interact with T3 liganded TR{beta} included ARA55, all of the TRAP100 peptides, and some of the RIP140 and DAX1 NR box peptides. The remaining coregulator peptides bound to TR{beta} weakly with Kd values ranging from 10 to 30 µM or > 30 µM as discussed above.

The SRCs are a family of coregulators whose interaction with TR{beta} have been extensively studied using non-quantitative methods (15, 38, 43, 44). Our data are consistent with previously published work where it was determined that TR{beta} has a strong preference for SRC2 NR box peptides with the overall observed preference being SRC2-2 > SRC2-3 > SRC2-1 (15). The next family member, SRC1, bound to liganded TR{beta} to a lesser extent with SRC1-2 ~ SRC1-3 > SRC1-1. Only weak interactions were observed for SRC3 where affinity has been reported as SRC3-2 > SRC3-1 = SRC3-3.

The TRAP coactivator complex has been shown to associate with NRs and help initiate transcription (19, 20). Two single subunits TRAP220 and TRAP100 were investigated for their ability to interact with liganded TR{beta}. TRAP220 has two NR boxes and in this report it was determined that the first NR box, TRAP220-1, interacted more strongly than the second NR box, TRAP220-2. This is the opposite of what has been reported for TR{alpha}, supporting the notion that TR isoforms can differentially recruit coactivator NR boxes (20, 45). The TRAP100 protein contains 7 NR boxes, 5 of which were studied here. As previously reported, none of these NR boxes interact with liganded TR{beta} (19).

Another coregulator that has been shown to interact with TR{beta} is TRBP. This coactivator is ubiquitously expressed and appears to be a general coactivator that can associate with NR including TR, ER, PPAR, as well as other transcriptional proteins such as AP-1, CRE, and NF{kappa}B-response element (25). There are two LXXLL motifs in TRBP and both can interact with TR{beta}. Our studies indicate that TRBP-1 is preferentially recruited to TR{beta} in the presence of T3.

RIP140 is a coregulator that contains 9 LXXLL motifs and has been shown to interact with many NRs including TR{beta} (23). It has been suggested that RIP140 directly competes with other coregulators (23). Unlike traditional coregulators, however, RIP140 represses transcription upon binding to NR (46-49). Here we show liganded TR{beta} has a clear preference for three of the NR boxes in RIP140, RIP140-3, RIP140-5, and RIP140-8. One NR box peptide in particular, RIP140-5, bound fairly tightly with a Kd of 2.5 µM ± 0.4.

Three additional coactivators, p300, ARA70, and DAX1, were also shown in this report to associate with TR{beta} with varying degrees. ARA70 and DAX1 had not previously been investigated for their interaction with TR{beta}.

Ligands Alter Coregulator Recruitment—To investigate ligand effects on coregulator recruitment, binding studies were performed in the presence of the TR{beta} selective agonist, GC-1. GC-1 is a halogen-free thyromimetic that is ~10-fold selective for binding to TR{beta} versus TR{alpha} (39). It has been shown that the oxyacetic acid at the carbon-1 position (Fig. 3A) is responsible for the selective TR{beta} binding of GC-1 (50). Additionally, crystallographic studies have confirmed that the oxyacetic acid group participates in a hydrogen bonding network in the TR{beta} LBD polar pocket (51). We sought to determine how these interactions might alter coregulator specificity.

In the presence of GC-1 the coregulator peptides bound to TR{beta} with varying degrees of affinity and all four binding modes were observed. Overall the coregulator binding patterns for GC-1 and T3 were similar in terms of which coregulator peptides were recruited. However, the degree to which they bound varied. In most cases, the coregulator peptides bound with similar or slightly lower affinity to TR{beta}·GC-1 than to TR{beta}·T3. Several NR boxes, particularly those of the SRC family, exhibited significant differences in affinity to TR{beta}·GC-1 relative to TR{beta}·T3. All of the SRC2 NR boxes bound TR{beta}·T3 in a measurable Kd range, whereas in the presence of GC-1 a saturated binding curve was only observed for SRC2-2. Additionally, SRC1-2 appears to be much more strongly recruited by TR{beta}·T3, whereas the opposite is true for SRC3-3. Other notable differences between T3 and GC-1 were seen with TRAP220 and TRBP where recruitment decreased in the presence of GC-1.

In addition to studying agonist induced coregulator recruitment, we wanted to explore how antagonists may affect coregulator binding. The recently reported T3 antagonist NH-3 (Fig. 3A) was tested against the entire coregulator peptide library (40). In the presence of saturating concentrations of NH-3, no coregulators from the library were recruited to the TR{beta}·NH-3 complex (Fig. 3A).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The NRs show a clear preference for particular NR boxes. One factor that drives this specificity is the amino acid residues immediately flanking the NR box (15, 34, 36-38). Most prior work focused on individual coregulators or the p160/SRC coregulator family (15, 19, 23, 25, 38, 43-45, 52). To expand our understanding of coregulator recruitment, we investigated the ability of TR{beta} to bind to a library of known coregulator NR boxes using a homogenous equilibrium binding assay. The results from this screen demonstrate that the coregulator binding pattern for TR{beta} is distinct from other NR (ER{alpha}, ER{beta}, AR, data not shown) and new TR{beta}-coregulator peptide interactions, including RIP140-5 (Kd = 2.5 µM), ARA70 (Kd = 10-30 µM), and DAX1-3 (Kd = 3.6 µM) were identified. The NR box peptides that interacted with TR{beta} revealed specificity elements including a propensity for hydrophobic groups at the -1 position and for proline at the -2 position as seen in TRAP220 and TRBP-1 (20, 45). Additional trends included histidine at -3, glutamine at +6, and the presence of a serine in the C-terminal positions +7 to +10 (Fig. 3B). Previous phage display studies isolated non-natural peptides with similar specificity determinants (35).

Ligands are another factor that can impact the recruitment of coregulators to NR (36-38,53). In this study, the ability of both agonists and antagonists to modulate the coactivator binding pocket of TR{beta} was investigated. As predicted, the NR box binding patterns for TR{beta}·T3 and TR{beta}·GC-1 were different, and no coregulators were recruited in the presence of the T3 antagonist NH-3. Based on the differential NR box recruitment observed for the GC-1 ligand, specificity determinants that are distinct from T3 can be defined. While there is still a high propensity for hydrophobic amino acids at the -1 position and for serine at positions +7 to +10, proline at -2 and histidine at -3 do not seem to be important for specificity in the presence of GC-1 (Fig. 3B). In addition, the specificity determinants for TR{beta}·T3 and TR{beta}·GC-1 are distinct from those observed for the estrogen receptor with its cognate ligand (ER{alpha}·E2)(Chang et al. Ref. 35).

The differential binding patterns for TR{beta}·T3, TR{beta}·GC-1, and TR{beta}·NH-3 may be used to predict biological responses. In hypothyroid and euthyroid hypercholesterolemic mice, GC-1 behaves like T3 to potently reduce serum cholesterol (54). Additionally, while T3 potently induces positive inotropic and chronotropic cardiac effects, GC-1 is devoid of significant cardiac effects through a wide dose range. Although these observations may be partially explained by the selective binding of GC-1 to TR{beta} as well as preferential liver versus heart uptake (54), coregulator selectivity may also play a role. In the presence of T3 there is a stronger preference for the recruitment of SRC1 and SRC2 coregulator peptides to TR{beta}, whereas SRC2 and SRC3 NR boxes are more strongly recruited to TR{beta}·GC-1. Recent investigations focusing on the SRC1 role in regulating T3-responsive genes have revealed that SRC1 is important for the pituitary-hypothalamus-thyroid axis and for T3 affects in the heart but not for regulation of hepatic genes that regulate cholesterol levels (55-57). This suggests that SRC2 and SRC3 regulate cholesterol-modulating genes in the liver. In support of this argument, studies have shown that SRC2 and SRC3 liver expression is increased in hypothyroid mice while there is a slight decrease in SRC1 expression (58).

Studies utilizing cDNA microarrays have revealed that thyroid hormone can both positively and negatively regulate genes (59). One mechanism of T3-driven repression may involve the recruitment of coregulators that repress transcription, such as RIP140 and DAX1. In our studies we find that both TR{beta}·T3 and TR{beta}·GC-1 strongly interact with RIP140-5 and DAX1-3, but TR{beta}·NH-3 fails to recruit these coregulators. From these observations, it can be predicted that T3 and GC-1 can repress gene transcription but NH-3 lacks this ability. Thus NH-3 treatment may result in partial activation of genes that are normally repressed by TR{beta}·T3. If this is the case, then NH-3 would display unique pharmacology by blocking ligand activation of positively regulated T3-responsive genes and causing derepression of negatively regulated T3-responsive genes.

Presumably there are additional factors that influence NR recruitment of coregulators such as post-translational modifications, structural determinants arising from specific DNA response elements, cooperativity, cellular environment, and additional interaction surfaces on the NR and coregulator proteins. To fully dissect NR-coregulator interactions, more complex models will need to be developed. The use of full-length molecules for determining NR-coregulator binding affinities has been employed with the estrogen receptors and members of the SRC family (60). Although this work demonstrated that the binding affinities are 3-5 fold higher than predicted with coregulator peptides and NR-LBD, the overall selectivity of ER isoforms for SRC members was consistent with previous investigations. This emphasizes the utility of a simple affinity model as a first step for establishing rules of NR-coregulator selectivity.

NR signaling is a multivariant complex process that utilizes differences in NR, NR isoforms, a diverse set of coregulators, ligands, tissue variability, and unique DNA response elements. It remains unclear how this protein network can potentiate signals for specific biological responses. However one point of regulation may derive from specific NR-coregulator interactions. Using an equilibrium binding assay, the binding affinities of TR{beta} for a large set of NR boxes in the presence of multiple ligands were quantitatively determined and some rules were defined that account for the specificity of these interactions. Additionally, it was shown that these binding patterns could be used to predict biological responses. Finally, we believe that this method may be generalized to other nuclear receptors to establish patterns of NR-coregulator selectivity.


   FOOTNOTES
 
* This work was supported by Department of Defense Grant DAMD17-01-1-0188, the Sandler Research Foundation, National Institutes of Health Grants DK-52798 and DK-58390, the Center for Advanced Technology, and the Genomics and Proteomics Center. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

The on-line version of this article (available at http://www.jbc.org) contains Supplementary Data. Back

§ Current Address: 600 University Ave., Samuel Lunenfeld Research Institute, Mount Sinai Hospital Toronto, Ontario M5G 1X5, Canada. Back

|| To whom correspondence should be addressed. E-mail: rguy{at}cgl.ucsf.edu.

1 The abbreviations used are: T3, 3,3',5,-triiodo-L-thyronine; AR, androgen receptor; ARA70, androgen receptor activator; ER, estrogen receptor; LBD, ligand binding domain; NID, nuclear interaction domain; NR, nuclear receptor, PPAR, peroxisome proliferating-activated receptor; RIP140, receptor-interacting protein 140; SHP, small heterodimer partner; SRC steroid receptor coactivator; TR, thyroid hormone receptor; TRAP, thyroid receptor-activating protein; TRBP, thyroid receptor-binding protein; TRE, thyroid receptor response element; AD, activation domain; Fmoc, fluorenylmethoxycarbonyl. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Braverman, L. E., and Utiger, R. D. (1991) The Thyroid: A Fundamental and Clinical Text, Lippencott, Philadelphia, PA
  2. Greenspan, F. S. (1997) The Thyroid Gland, Basic & Clinical Endocrinology, Appleton & Lange, Stamford, CT
  3. Lazar, M. A., and Chin, W. W. (1990) J. Clin. Investig. 86, 1777-1782[Medline] [Order article via Infotrieve]
  4. Lazar, M. A. (1993) Endocr. Rev. 14, 184-193[Abstract/Free Full Text]
  5. Flamant, F., and Samarut, J. (2003) Trends Endocrinol. Metab. 14, 85-90[CrossRef][Medline] [Order article via Infotrieve]
  6. Forrest, D., Hanebuth, E., Smeyne, R. J., Everds, N., Stewart, C. L., Wehner, J. M., and Curran, T. (1996) EMBO J. 15, 3006-3015[Medline] [Order article via Infotrieve]
  7. Forrest, D., Golarai, G., Connor, J., and Curran, T. (1996) Recent Prog. Horm. Res. 51, 1-22[Medline] [Order article via Infotrieve]
  8. Fraichard, A., Chassande, O., Plateroti, M., Roux, J. P., Trouillas, J., Dehay, C., Legrand, C., Gauthier, K., Kedinger, M., Malaval, L., Rousset, B., and Samarut, J. (1997) EMBO J. 16, 4412-4420[CrossRef][Medline] [Order article via Infotrieve]
  9. Gauthier, K., Chassande, O., Plateroti, M., Roux, J. P., Legrand, C., Pain, B., Rousset, B., Weiss, R., Trouillas, J., and Samarut, J. (1999) EMBO J. 18, 623-631[CrossRef][Medline] [Order article via Infotrieve]
  10. Ng, L., Hurley, J. B., Dierks, B., Srinivas, M., Salto, C., Vennstrom, B., Reh, T. A., and Forrest, D. (2001) Nat. Genet. 27, 94-98[Medline] [Order article via Infotrieve]
  11. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., and Chambon, P. (1995) Cell 83, 835-839[CrossRef][Medline] [Order article via Infotrieve]
  12. Umesono, K., Murakami, K. K., Thompson, C. C., and Evans, R. M. (1991) Cell 65, 1255-1266[CrossRef][Medline] [Order article via Infotrieve]
  13. Leo, C., and Chen, J. D. (2000) Gene (Amst.) 245, 1-11[CrossRef][Medline] [Order article via Infotrieve]
  14. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) Nature 387, 733-736[CrossRef][Medline] [Order article via Infotrieve]
  15. Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J., and Yamamoto, K. R. (1998) Genes Dev. 12, 3343-3356[Abstract/Free Full Text]
  16. Wagner, R. L., Apriletti, J. W., McGrath, M. E., West, B. L., Baxter, J. D., and Fletterick, R. J. (1995) Nature 378, 690-697[CrossRef][Medline] [Order article via Infotrieve]
  17. Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859[CrossRef][Medline] [Order article via Infotrieve]
  18. Eckner, R., Arany, Z., Ewen, M., Sellers, W., and Livingston, D. M. (1994) Cold Spring Harb. Symp. Quant. Biol. 59, 85-95[Abstract/Free Full Text]
  19. Zhang, J., and Fondell, J. D. (1999) Mol. Endocrinol. 13, 1130-1140[Abstract/Free Full Text]
  20. Yuan, C. X., Ito, M., Fondell, J. D., Fu, Z. Y., and Roeder, R. G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7939-7944[Abstract/Free Full Text]
  21. Yeh, S., Sampson, E. R., Lee, D. K., Kim, E., Hsu, C. L., Chen, Y. L., Chang, H. C., Altuwaijri, S., Huang, K. E., and Chang, C. (2000) J. Formos. Med. Assoc. 99, 885-894[Medline] [Order article via Infotrieve]
  22. Heinlein, C. A., Ting, H. J., Yeh, S., and Chang, C. (1999) J. Biol. Chem. 274, 16147-16152[Abstract/Free Full Text]
  23. Treuter, E., Albrektsen, T., Johansson, L., Leers, J., and Gustafsson, J. A. (1998) Mol. Endocrinol. 12, 864-881[Abstract/Free Full Text]
  24. Esterbauer, H., Oberkofler, H., Krempler, F., and Patsch, W. (1999) Genomics 62, 98-102[CrossRef][Medline] [Order article via Infotrieve]
  25. Ko, L., Cardona, G. R., and Chin, W. W. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6212-6217[Abstract/Free Full Text]
  26. Zhu, Y., Kan, L., Qi, C., Kanwar, Y. S., Yeldandi, A. V., Rao, M. S., and Reddy, J. K. (2000) J. Biol. Chem. 275, 13510-13516[Abstract/Free Full Text]
  27. Suzuki, T., Kasahara, M., Yoshioka, H., Morohashi, K., and Umesono, K. (2003) Mol. Cell. Biol. 23, 238-249[Abstract/Free Full Text]
  28. Johansson, L., Bavner, A., Thomsen, J. S., Farnegardh, M., Gustafsson, J. A., and Treuter, E. (2000) Mol. Cell. Biol. 20, 1124-1133[Abstract/Free Full Text]
  29. Xu, H. E., Stanley, T. B., Montana, V. G., Lambert, M. H., Shearer, B. G., Cobb, J. E., McKee, D. D., Galardi, C. M., Plunket, K. D., Nolte, R. T., Parks, D. J., Moore, J. T., Kliewer, S. A., Willson, T. M., and Stimmel, J. B. (2002) Nature 415, 813-817[Medline] [Order article via Infotrieve]
  30. Xu, J., Liao, L., Ning, G., Yoshida-Komiya, H., Deng, C., and O'Malley, B. W. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6379-6384[Abstract/Free Full Text]
  31. Weiss, R. E., Xu, J., Ning, G., Pohlenz, J., O'Malley, B. W., and Refetoff, S. (1999) EMBO J. 18, 1900-1904[CrossRef][Medline] [Order article via Infotrieve]
  32. Weiss, R. E., Gehin, M., Xu, J., Sadow, P. M., O'Malley, B. W., Chambon, P., and Refetoff, S. (2002) Endocrinology 143, 1554-1557[Abstract]
  33. Li, X., Wong, J., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (2003) Mol. Cell. Biol. 23, 3763-3773[Abstract/Free Full Text]
  34. Northrop, J. P., Nguyen, D., Piplani, S., Olivan, S. E., Kwan, S. T., Go, N. F., Hart, C. P., and Schatz, P. J. (2000) Mol. Endocrinol. 14, 605-622[Abstract/Free Full Text]
  35. Chang, C., Norris, J. D., Gron, H., Paige, L. A., Hamilton, P. T., Kenan, D. J., Fowlkes, D., and McDonnell, D. P. (1999) Mol. Cell. Biol. 19, 8226-8239[Abstract/Free Full Text]
  36. Bramlett, K. S., Wu, Y., and Burris, T. P. (2001) Mol. Endocrinol. 15, 909-922[Abstract/Free Full Text]
  37. Geistlinger, T. R., McReynold, A. C., Guy, R. K. (2004) Chemistry and Biology 11, 273-281[CrossRef][Medline] [Order article via Infotrieve]
  38. McInerney, E. M., Rose, D. W., Flynn, S. E., Westin, S., Mullen, T. M., Krones, A., Inostroza, J., Torchia, J., Nolte, R. T., Assa-Munt, N., Milburn, M. V., Glass, C. K., and Rosenfeld, M. G. (1998) Genes Dev. 12, 3357-3368[Abstract/Free Full Text]
  39. Chiellini, G., Apriletti, J. W., Yoshihara, H. A., Baxter, J. D., Ribeiro, R. C., and Scanlan, T. S. (1998) Chem. Biol. 5, 299-306[CrossRef][Medline] [Order article via Infotrieve]
  40. Nguyen, N. H., Apriletti, J. W., Cunha Lima, S. T., Webb, P., Baxter, J. D., and Scanlan, T. S. (2002) J. Med. Chem. 45, 3310-3320[CrossRef][Medline] [Order article via Infotrieve]
  41. Wellings, D. A., and Atherton, E. (1997) Methods Enzymol. 289, 44-67[CrossRef][Medline] [Order article via Infotrieve]
  42. Coulthard, V. H., Matsuda, S., and Heery, D. M. (2003) J. Biol. Chem. 278, 10942-10951[Abstract/Free Full Text]
  43. Takeshita, A., Cardona, G. R., Koibuchi, N., Suen, C. S., and Chin, W. W. (1997) J. Biol. Chem. 272, 27629-27634[Abstract/Free Full Text]
  44. Li, H., Gomes, P. J., and Chen, J. D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8479-8484[Abstract/Free Full Text]
  45. Ren, Y., Behre, E., Ren, Z., Zhang, J., Wang, Q., and Fondell, J. D. (2000) Mol. Cell. Biol. 20, 5433-5446[Abstract/Free Full Text]
  46. Subramaniam, N., Treuter, E., and Okret, S. (1999) J. Biol. Chem. 274, 18121-18127[Abstract/Free Full Text]
  47. Cavailles, V., Dauvois, S., L'Horset, F., Lopez, G., Hoare, S., Kushner, P. J., and Parker, M. G. (1995) EMBO J. 14, 3741-3751[Medline] [Order article via Infotrieve]
  48. Mellgren, G., Borud, B., Hoang, T., Yri, O. E., Fladeby, C., Lien, E. A., and Lund, J. (2003) Mol. Cell. Endocrinol. 203, 91-103[CrossRef][Medline] [Order article via Infotrieve]
  49. Miyata, K. S., McCaw, S. E., Meertens, L. M., Patel, H. V., Rachubinski, R. A., and Capone, J. P. (1998) Mol. Cell. Endocrinol. 146, 69-76[CrossRef][Medline] [Order article via Infotrieve]
  50. Yoshihara, H. A., Apriletti, J. W., Baxter, J. D., and Scanlan, T. S. (2003) J. Med. Chem. 46, 3152-3161[CrossRef][Medline] [Order article via Infotrieve]
  51. Wagner, R. L., Huber, B. R., Shiau, A. K., Kelly, A., Cunha Lima, S. T., Scanlan, T. S., Apriletti, J. W., Baxter, J. D., West, B. L., and Fletterick, R. J. (2001) Mol. Endocrinol. 15, 398-410[Abstract/Free Full Text]
  52. Wu, Y., Delerive, P., Chin, W. W., and Burris, T. P. (2002) J. Biol. Chem. 277, 8898-8905[Abstract/Free Full Text]
  53. Kodera, Y., Takeyama, K., Murayama, A., Suzawa, M., Masuhiro, Y., and Kato, S. (2000) J. Biol. Chem. 275, 33201-33204[Abstract/Free Full Text]
  54. Trost, S. U., Swanson, E., Gloss, B., Wang-Iverson, D. B., Zhang, H., Volodarsky, T., Grover, G. J., Baxter, J. D., Chiellini, G., Scanlan, T. S., and Dillmann, W. H. (2000) Endocrinology 141, 3057-3064[Abstract/Free Full Text]
  55. Takeuchi, Y., Murata, Y., Sadow, P., Hayashi, Y., Seo, H., Xu, J., O'Malley, B. W., Weiss, R. E., and Refetoff, S. (2002) Endocrinology 143, 1346-1352[Abstract/Free Full Text]
  56. Sadow, P. M., Koo, E., Chassande, O., Gauthier, K., Samarut, J., Xu, J., O'Malley, B. W., Seo, H., Murata, Y., and Weiss, R. E. (2003) Mol. Endocrinol. 17, 882-894[Abstract/Free Full Text]
  57. Sadow, P. M., Chassande, O., Gauthier, K., Samarut, J., Xu, J., O'Malley, B. W., and Weiss, R. E. (2003) Am. J. Physiol. Endocrinol. Metab. 284, E36-46[Abstract/Free Full Text]
  58. Sadow, P. M., Chassande, O., Koo, E. K., Gauthier, K., Samarut, J., Xu, J., O'Malley, B. W., and Weiss, R. E. (2003) Mol. Cell. Endocrinol. 203, 65-75[CrossRef][Medline] [Order article via Infotrieve]
  59. Feng, X., Jiang, Y., Meltzer, P., and Yen, P. M. (2000) Mol. Endocrinol. 14, 947-955[Abstract/Free Full Text]
  60. Cheskis, B. J., McKenna, N. J., Wong, C. W., Wong, J., Komm, B., Lyttle, C. R., and O'Malley, B. W. (2003) J. Biol. Chem. 278, 13271-13277[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
E. P. Sablin, A. Woods, I. N. Krylova, P. Hwang, H. A. Ingraham, and R. J. Fletterick
The structure of corepressor Dax-1 bound to its target nuclear receptor LRH-1
PNAS, November 25, 2008; 105(47): 18390 - 18395.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Xia, A. Webster, F. Du, K. Piatkov, M. Ghislain, and A. Varshavsky
Substrate-binding Sites of UBR1, the Ubiquitin Ligase of the N-end Rule Pathway
J. Biol. Chem., August 29, 2008; 283(35): 24011 - 24028.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. J. Grover, C. Dunn, N.-H. Nguyen, J. Boulet, G. Dong, J. Domogauer, P. Barbounis, and T. S. Scanlan
Pharmacological Profile of the Thyroid Hormone Receptor Antagonist NH3 in Rats
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 385 - 390.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P.-J. Tai, Y.-H. Huang, C.-H. Shih, R.-N. Chen, C.-D. Chen, W.-J. Chen, C.-S. Wang, and K.-H. Lin
Direct Regulation of Androgen Receptor-Associated Protein 70 by Thyroid Hormone and Its Receptors
Endocrinology, July 1, 2007; 148(7): 3485 - 3495.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
L. A. Arnold, E. Estebanez-Perpina, M. Togashi, A. Shelat, C. A. Ocasio, A. C. McReynolds, P. Nguyen, J. D. Baxter, R. J. Fletterick, P. Webb, et al.
A High-Throughput Screening Method to Identify Small Molecule Inhibitors of Thyroid Hormone Receptor Coactivator Binding
Sci. Signal., June 27, 2006; 2006(341): pl3 - pl3.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. A. Arnold, E. Estebanez-Perpina, M. Togashi, N. Jouravel, A. Shelat, A. C. McReynolds, E. Mar, P. Nguyen, J. D. Baxter, R. J. Fletterick, et al.
Discovery of Small Molecule Inhibitors of the Interaction of the Thyroid Hormone Receptor with Transcriptional Coregulators
J. Biol. Chem., December 30, 2005; 280(52): 43048 - 43055.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. M. R. Moore and R. K. Guy
Coregulator Interactions with the Thyroid Hormone Receptor
Mol. Cell. Proteomics, April 1, 2005; 4(4): 475 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Estebanez-Perpina, J. M. R. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J. D. Baxter, B. M. Buehrer, P. Webb, R. J. Fletterick, and R. K. Guy
The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor
J. Biol. Chem., March 4, 2005; 280(9): 8060 - 8068.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
279/26/27584    most recent
M403453200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, J. M. R.
Right arrow Articles by Guy, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, J. M. R.
Right arrow Articles by Guy, R. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement